Zepbound Beats Higher-Dose Wegovy in Weight Loss Analysis
LLY sits 66% above its 52-week low of $716.078.
Summary
Lilly's Zepbound showed 3.2% and 4.5% greater weight loss than Novo's higher-dose Wegovy HD at 72 weeks in an indirect comparison. This adds to prior head-to-head data favoring Zepbound over standard Wegovy doses. The analysis strengthens Lilly's competitive position in the GLP-1 obesity market, where it already leads with Mounjaro and Zepbound. The data may influence prescribing decisions and payer coverage, potentially widening Lilly's market share lead. Watch for Novo's response and any regulatory or labeling updates.
At the time of this announcement, LLY was trading at $1,186.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $716.08 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.